![CrossMark Logo]({"type":"image" , "src":"/templates/jsp/images/CROSSMARK_Color_horizontal.svg"})
Abstract
Objective: The human leukocyte antigen (HLA) is the strongest genetic risk factor for idiopathic inflammatory myopathy (IIM), and different HLA alleles have been reported to be associated with IIM susceptibility among different ethnic groups. In this study, we have investigated HLA alleles associated with IIM in Japanese patients.
Methods: Genotyping of HLA-DRB1 and DPB1 were performed in 252 Japanese IIM patients (166 dermatomyositis [DM] and 86 polymyositis [PM] patients) and the association was analyzed with comparison to controls (n = 1026 for DRB1 and n = 413 for DPB1).
Results: DRB1*08:03 was associated with IIM (p = 1.60 × 10−5, pc = .0005, odds ratio [OR] 2.11, 95% confidence interval [CI] 1.52–2.92) and DM (p = .0004, pc = .0128, OR 2.06, 95%CI 1.40–3.02). DPB1*05:01 was also associated with IIM (p = .0001, pc = .0021, OR 1.96, 95%CI 1.38–2.77) and DM (p = .0005, pc = .0075, OR 2.05, 95%CI 1.37–3.08). DRB1*09:01 (p = .0012, pc = .0368, OR 0.35, 95% CI 0.18–0.69) and DPB1*04:01(p = .0004, pc = .0057, OR 0.05, 95% CI 0.00–0.85) were protectively associated with PM. Two locus analyses suggested that DRB1*09:01 and DPB1*04:01 were independently associated with PM.
Conclusion: Protective associations of HLA were detected in Japanese PM patients.
Acknowledgments
The authors thank Ms Mayumi Yokoyama (Department of Rheumatology, National Hospital Organization Tokyo National Hospital) and Ms Satomi Hanawa (Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital) for secretarial assistance.
Conflict of interest
H. F. has the following conflict of interests; the Takeda Science Foundation is supported by an endowment from Takeda Pharmaceutical Company. H. F. was supported by research grants from Bristol-Myers Squibb Co. HF received honoraria from Ajinomoto Co., Inc., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Pfizer Japan Inc., and Takeda Pharmaceutical Company, Luminex Japan Corporation Ltd., and Ayumi Pharmaceutical Corporation. NT has received a research grant from Bristol-Myers Squibb, 2015 Japan College of Rheumatology Award from Japan College of Rheumatology and 2017 Novartis Rheumatology Award from Japan Rheumatism Association with research funding, and speaker’s honoraria from Ayumi Pharmaceutical Corporation. S. T. was supported by research grants from nine pharmaceutical companies: Abbott Japan Co., Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Merck Sharp and Dohme Inc., Pfizer Japan Inc., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited. S. T. received honoraria from Asahi Kasei Pharma Corporation, Astellas Pharma Inc., AbbVie GK., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc. The other authors declare no financial or commercial conflict of interests.
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/JournalAd-Sample-Our-Journals-Medicine-PB.gif"})
![Your research. Your choice. How-to guide for authors.]({"type":"image" , "src" : "/sda/110303/JournalAd-Your-Research-Your-Choice-SW.gif"})
![Annals of medicine, now fully Open Access!]({"type":"image" , "src" : "/sda/110585/IANN-Rheumatology.gif"})